AstraZeneca Pharma India Limited declared a dividend of ₹36 per equity share during its 47th Annual General Meeting (AGM) held on August 10, 2026. The meeting, conducted via Video Conferencing and Other Audio Visual Means, also approved the reappointment of Bhavana Agrawal and the appointment of BSR & Co. LLP as the company’s statutory auditors for the upcoming term.

The AGM commenced at 3:18 P.M., after the requisite quorum was established, having been scheduled for 3:00 P.M. The meeting concluded at 5:20 P.M. Shareholders exercised their voting rights through remote e-voting from August 6, 2026, at 9:00 a.m. to August 9, 2026, at 5:00 p.m. Members attending via VC/OAVM who had not voted remotely were provided e-voting facilities on the NSDL portal during the meeting.

Key Resolutions Passed

The Board of Directors placed five ordinary business items before the shareholders for approval:

Bhavana Agrawal, who retires by rotation, offered herself for reappointment and was approved by the shareholders. Shilpa Divekar Nirula was reappointed as an Independent Director for a second consecutive term of five years, commencing from December 29, 2026, and ending on December 28, 2031.

Compliance and Regulatory Filings

The proceedings were conducted in accordance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the summary of proceedings.

The final voting results will be announced upon receipt of the Scrutinizer’s Report. These results will be submitted to the exchanges in compliance with Regulation 44(3) of the SEBI LODR Regulations, 2015. The company secretary, Tanya Sanish, certified the proceedings.

AstraZeneca Pharma India Limited received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) on August 7, 2026, to import and distribute Enhertu for an additional indication in the treatment of breast cancer. The permission allows the company to market Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion in India for this specific use case, subject to any remaining statutory approvals.

The approval expands the therapeutic application of Enhertu to include the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer. Specifically, it targets patients who have residual invasive disease following neoadjuvant treatment with Trastuzumab, with or without Pertuzumab, combined with taxane-based therapy. This development enables AstraZeneca to address a critical gap in post-neoadjuvant care for high-risk HER2-positive patients.

Regulatory Details

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Limited on August 8, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The CDSCO, operating under the Directorate General of Health Services of the Government of India, granted the permission to import the drug for sale and distribution.

Clinical Indication Scope

The newly approved indication focuses on the adjuvant setting, which involves treatment given after primary surgery or other initial therapies to reduce the risk of cancer recurrence. The eligibility criteria require patients to have HER2-positive status confirmed via IHC 3+ or ISH+ testing. Furthermore, patients must exhibit residual invasive disease despite undergoing prior neoadjuvant regimens involving Trastuzumab and taxanes.

What This Means for Market Access

This regulatory milestone paves the way for AstraZeneca Pharma India to commercialize Enhertu for this specific patient segment. While the CDSCO approval is a decisive step, the company noted that marketing activities remain subject to the receipt of related statutory approvals, if any. The expansion of indications strengthens AstraZeneca’s oncology portfolio in the Indian market, offering a targeted solution for patients who do not achieve complete pathological response to standard neoadjuvant therapies.